A Agilent Technologies Inc.

Agilent Resolve Raman Receives Multiple Recognitions for HazMat and CBRN Excellence

(NYSE: A) today announced that the Agilent has been recognized for excellence as a tool for emergency responders following independent use and evaluation by both the UK’s National CBRN Centre, and the US’ Department of Homeland Security.

In the United Kingdom, the Resolve instrument received the Certificate of Merit for 2023. The CBRN Certificate of Merit award recognizes the value of the Resolve instrument, and the added services and responsivity Agilent provides to its customers. The award was presented in recognition of Agilent’s ongoing service and support to the National CBRN Centre and multi-agency partners, strengthening the UK’s ability to respond to chemical, biological, radiological, and nuclear threats.

The National CBRN Centre (NCBRNC) brings together the emergency services and wider partners to protect and prepare the UK against the chemical, biological, radiological, and nuclear (CBRN) threat. This certificate is confirmation that all these services based in the UK recognize the benefits of the Agilent Resolve Handheld Raman Spectrometer.

“Partnerships with existing and new suppliers across the broad spectrum that CBRN response require have meant that we are able to assure the UK response to a CBRN incident,” explained Inspector Scott Howard, National CBRN Centre, Counter Terrorism Policing. “This is why Agilent, as an equipment supplier to the NCBRNC, was awarded a Certificate of Merit by the Head of Centre in recognition of the ongoing service and support provided to us and our multi-agency partners. This support has ultimately strengthened the UK response to counter-terrorism incidents involving CBRN material, and for that, we are truly grateful.”

In the United States, the Agilent Resolve was awarded the highest overall score amongst handheld Raman devices available in the market in an conducted by the Department of Homeland Security's . In the independent evaluation performed by emergency responders, the Resolve also scored the highest in the "Capability" criterion, exceeding the expectations of all evaluators as it correctly identified samples through all containers used at the assessment. This ability reduces the risk of accidental exposure of operators and the public to hazardous materials.

“Both the National CBRN Centre Certificate of Merit award and the SAVER evaluation reflect Agilent’s aspiration to supply the best possible solutions and services for our customers who put themselves in harm’s way to protect the public every day,” said Robert Stokes, Field Detection Marketing Director at Agilent. “These accolades are an important recognition of the Resolve being a key apparatus choice for emergency responders across the globe.”

The Agilent Resolve instrument utilizes proprietary spatially offset Raman spectroscopy (SORS) technology designed to enable positive identification through a wide range of sealed nonmetallic containers, barriers, and packaging. The world’s only handheld Raman system enables true through-barrier identification of hazardous or contraband materials.

About Agilent Technologies

(NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on and .

EN
07/12/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch